Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. 2004N-0179]
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).
 DATES: Fax written comments on the collection of information by December 3, 2004.
 ADDRESSES: OMB is still experiencing significant delays in the regular mail, including first class and express mail, and messenger deliveries are not being accepted. To ensure that comments on the information collection are received, OMB recommends that written 
                        ( print page 64072)
                        comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn:  Fumie Yokota, Desk Officer for FDA, FAX:  202-395-6974.
 FOR FURTHER INFORMATION CONTACT: Denver Presley, Office of Management Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1472.


SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. New Animal Drug  Application, Form 356 V—21 CFR Part 514 (OMB Control Number 0910-0032)—Extension FDA has the responsibility under the Federal Food, Drug and Cosmetic Act (the act), for the approval of new animal drugs that are safe and effective.  Section 512(b) of the act (21 U.S.C. 360b(b)) requires that a sponsor submit and receive approval of a new animal drug application (NADA) before interstate marketing is allowed. The regulations implementing statutory requirements for NADA approval have been codified under 21 CFR part 514.  NADA applicants generally use a single form, FDA 356 V.  The NADA must contain, among other things, safety and effectiveness data for the drug, labeling, a list of components, manufacturing and controls information, and complete information on any methods used to determine residues  of drug chemicals in edible tissues.  While the NADA is pending, an amended application may be submitted for proposed changes. After an NADA has been approved, a supplemental application must be submitted for certain proposed changes, including changes beyond the variations provided for in the NADA and other labeling changes.  An amended application and a supplemental application may omit statements concerning which no change is proposed.  This information is reviewed by FDA scientific personnel to ensure that the intended use of an animal drug, whether as a pharmaceutical dosage form, in drinking water, or in medicated feed, is safe and effective.  The respondents are pharmaceutical firms that produce veterinary products and commercial feed mills. In the 
                    **Federal Register**
                     of May 19, 2004 (69 FR 28930), FDA published a 60-day notice soliciting comments on the collection of information requirements.  In response to that notice, no comments were received. FDA estimates the burden of this collection of information as follows: **Table 1.—Estimated Annual Reporting Burden**1
21 CFR Section
No. of Respondents
Annual Frequency per Response
Total Annual Responses
Hours per Response
Total Hours514.1 and 514.6
190
7.39
1,405
211.6
297,298514.8
190
7.39
1,405
30
42,150514.11
190
7.39
1,405
1
1,405558.5(i)
1
1
1.0
5
5Total
340,8581
                         There are no capitol costs or operating and maintenance costs associated with this collection of information.
 The estimate of the burden hours required for reporting are based on FY 2003 data. The burden estimate includes original NADAs, supplemental NADAs and amendments to unapproved applications. The burden estimate for obtaining a waiver (filing a petition) from labeling requirements for certain drugs intended for use in animal feed or drinking water was derived from data by FDA's Division of Animal Feeds in the Center for Veterinary Medicine. Dated: October 27, 2004. Jeffrey Shuren, Assistant Commissioner for Policy.


[FR Doc. 04-24446 Filed 11-2-04; 8:45 am] BILLING CODE 4160-01-S